Healthcare access and clinical operations
CVS Health Split: What It Means for Patient Access and Oncology Trials
Understand CVS Health’s proposed 2028 split, retained Aetna–Caremark–specialty pharmacy integration, and what oncology teams should watch for patient access.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
CVS Health announced a proposed separation on November 4, 2026, targeting the first half of 2028, subject to customary conditions. The company plans two publicly traded businesses. The proposed CVS Health would contain Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. CVS Pharmacy would contain approximately 9,000 retail pharmacies, mail pharmacy, MinuteClinic and Health100. [1, 2]
The distinction between retail and specialty pharmacy is central. Insurance, pharmacy benefit management and specialty dispensing would remain under common ownership. The proposal therefore separates part of the existing organization while retaining important elements of vertical integration. STAT's report highlights that continuing connection. [3]
CVS describes greater focus, affordability and access as objectives and says patients will continue receiving services without interruption. Those statements are company commitments; the announcement does not establish lower patient spending, faster treatment or better health outcomes. [1]
The policy backdrop predates this proposal. In January 2025, FTC staff reported large markups on selected specialty generic medicines dispensed by pharmacies affiliated with the three largest PBMs, including Caremark. The analysis concerned historical dispensing data, including cancer medicines. It is not an evaluation of the proposed split or a finding that this transaction will resolve pricing concerns. [4]
For oncology, the access question has clinical significance. The National Cancer Institute summarizes evidence associating financial burden with missed prescriptions, reduced adherence and other hardships. That evidence supports examining affordability; it does not predict outcomes from the CVS separation. [5]
What this means for trial teams
Lampgen's interpretation is that this proposal should be evaluated through the patient's experience: the amount paid, the time needed to obtain treatment, available pharmacy choices and continuity between providers. A corporate separation creates an opportunity to change operating incentives. Whether it does so remains an open question.
Affordability: compare out-of-pocket spending for equivalent coverage and treatment. A change in the corporate structure cannot, by itself, tell a patient what their next prescription will cost. Analyses should account for benefit design, formulary changes and other factors that could explain a difference.
Continuity: watch prescription transfers, referral handoffs and responsibility for resolving access problems. Where a service relationship changes, someone should own the handoff and the escalation path. These are proposed measures for the transition, not disruptions reported in today's announcement.
Equity: examine results across geography, insurance status and relevant patient groups. An improved overall average could conceal persistent barriers for people with limited transportation, fewer local care options or difficulty navigating coverage. The question is who can obtain treatment in practice.
For clinical trial teams, the immediate step is to review actual dependencies before changing a study plan. If a study uses affected commercial pharmacy services or referral arrangements, check whether contracts, data permissions, named contacts or escalation responsibilities will change. Today's announcement does not establish a new trial-site network, new recruitment capacity or a change to any specific protocol.
Keep commercially obtained routine-care and supportive medicines distinct from sponsor-supplied investigational products. For relevant studies, document the reason and dates of an access-related interruption so that an insurance delay is not confused with toxicity or a participant's decision to stop treatment. Investigators retain clinical decision-making responsibility; CRAs and clinical trial managers support reliable documentation, coordination and escalation.
Lampgen Clinical Research provides oncology CRA staffing and clinical-operations resourcing. Our perspective is that patient access and dependable study execution deserve explicit owners and measurable follow-through. The test for the proposed CVS split is whether patients can obtain and sustain appropriate care with less financial and administrative burden.
Sources
- [1] CVS Health separation announcement — November 4, 2026
- [2] CVS Health Form 8-K — November 4, 2026
- [3] STAT, Bob Herman: CVS split and retained specialty integration — November 4, 2026
- [4] FTC second interim PBM staff report announcement — January 14, 2025
- [5] National Cancer Institute: Financial Toxicity and Cancer Treatment